1. 1) Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681
2. 2) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017; 376: 1713-1722
3. 3) Shapiro MD, Fazio S: PCSK9 and Atherosclerosis-Lipids and Beyond. J Atheroscler Thromb, 2017; 24: 462-472
4. 4) Fujioka Y, Ishikawa Y: Remnant lipoproteins as strong key particles to atherosclerosis. J Atheroscler Thromb, 2009; 16: 145-154
5. 5) Masuda D, Yamashita S: Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb, 2017; 24: 95-109